FIELD: medicine; ophthalmology.
SUBSTANCE: invention is intended for simultaneous verification of uveal melanoma and forecast of metastasis development. Immunohistochemical analysis of protein S-100 and melanin-A expression within tumour cell is accompanied with simultaneous estimation of S-100-positive cells number within visual field. Uveal melanoma is verified if reaction of S-100 and melanin-A is positive with forecasted high possibility of tumour dissemination in case number of S-100-positive cells number is less than 50.
EFFECT: simplified examination associated with high specificity and sensibility of simultaneously verified uveal melanoma and forecasted metastasis.
1 tbl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SIMULTANEOUS VERIFICATION AND PREDICTION OF COURSE OF UVEAL MELANOMA | 2006 |
|
RU2337362C1 |
| METHOD FOR PREDICTION OF SURVIVAL RATE AFTER ENUCLEATION WITH UVEAL MELANOMA DEVELOPED TO EQUATOR | 2024 |
|
RU2822319C1 |
| METHOD OF PREDICTION OF CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER Bax | 2002 |
|
RU2208790C1 |
| METHOD FOR PREDICTING METASTASES OF UVEAL MELANOMA BASED UPON APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2242766C1 |
| METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS SPREAD WITH APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2244934C2 |
| METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS FORMATION ON THE BASIS OF BAX AND KI-67 MARKERS | 2003 |
|
RU2240560C1 |
| METHOD PREDICTING CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER p53 | 2002 |
|
RU2208789C1 |
| METHOD FOR PREDICTING CLINICAL FLOW OF UVEAL MELANOMA | 2001 |
|
RU2193200C1 |
| METHOD FOR DETECTING EFFICIENCY OF ANTI-TUMOR THERAPY OF SKIN MELANOMAS | 2004 |
|
RU2280483C2 |
| METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
